SCREENING MODULE Clause Samples
SCREENING MODULE. In the first module of the Research (the "SCREENING MODULE"), CombinatoRx shall screen a library of approximately 500 drug compounds in order to identify promising combination drugs for the potential treatment of SMA. The parties agree that the screening library will consist of drug molecules which are known to be able to cross the human blood-brain barrier. As promptly as practicable following the Effective Date, the parties shall work together to define the screening library for the Screening Module. For such screening, CombinatoRx shall use a fibroblast SMN protein induction assay optimized for combination high-throughput screening by CombinatoRx. CombinatoRx shall disclose the results of such screening to the Foundation in accordance with Section 2.6, and the parties shall consult with each other to select one or more combination drug candidates meeting the criteria set forth in the Research Plan (or otherwise mutually agreed upon by the parties) for further
SCREENING MODULE. For conduct of the Screening Module, the Foundation shall pay the following amounts to CombinatoRx upon occurrence of the applicable event specified below:
(i) Within 10 days of the Effective Date, the Foundation will pay to CombinatoRx US$190,000;
(ii) Within 30 days of the Foundation's receipt of the Research Report for the first quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000;
(iii) Within 30 days of the Foundation's receipt of the Research Report for the second quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000;
(iv) Within 30 days of the Foundation's receipt of the Research Report for the third quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000;
(v) Within 30 days of the Foundation's receipt of the Research Report for the fourth quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000; and
(vi) Within 30 days of the Foundation's receipt of the Research Report for the fifth quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000;